Given the increased role of LZTR1 as a RAS-regulator in hematologic cancers, this dual function may explain why A146 mutations are enriched in hematologic malignancies but are largely absent from pancreatic and many other epithelial cancers1. This evidence concerns the gene LZTR1 and hematopoietic and lymphoid cell neoplasm.